Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
95020 trials found · Page 149 of 4751
-
New study aims to spare breast cancer patients from Heart-Damaging chemo
Disease control Not yet recruitingIparomlimab and Tuvonralimab Injection (QL1706) is a bifunctional combination antibody targeting both programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4). This is a prospective clinical study that plans to enroll screened, eligible early-stage bre…
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated May 11, 2026 20:47 UTC
-
Viruses vs. superbugs: new hope for bone implant infections?
Disease control Not yet recruitingA Prospective, Single-Center, Single-Arm Clinical Study with a Pre-Post Self-Controlled Design Evaluating the Efficacy and Safety of Bacteriophage Therapy for Refractory Orthopedic Implant-Associated Infections
Phase: PHASE3 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New pill hopes to slow lung scarring in progressive pulmonary fibrosis
Disease control Not yet recruitingThis study is open to adults with PPF . The main objective is to evaluate of the efficacy and the secondary objective is to evaluate the safety and pharmacokinetic.
Phase: PHASE3 • Sponsor: Haisco Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated May 08, 2026 12:01 UTC
-
Could oxygen therapy save lives from Flesh-Eating infections?
Disease control Recruiting nowNecrotizing soft-tissue infection (NSTI) is a rare, severe, fast-progressing bacterial infection within the soft tissue compartment. The NSTI mortality rate remain high and largely unaltered in the last decades. The standard of care in NSTI is multidisciplinary and includes surge…
Phase: PHASE4 • Sponsor: Ole Hyldegaard • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
Could this pill stop Alzheimer's before it starts? new trial targets High-Risk gene carriers
Prevention Not yet recruitingPrimary Objectives: To demonstrate that HT-4253 improves the amyloid risk profile by transitioning biomarker-positive APOE4 carriers from a positive, high risk APS2 score to a negative, low risk APS2 score. Secondary Objectives: * To assess the effects of HT-4253 on tau relate…
Phase: PHASE2 • Sponsor: Halia Therapeutics, Inc. • Aim: Prevention
Last updated May 15, 2026 11:56 UTC
-
New hope for lung cancer patients: experimental drug RC148 enters final testing phase
Disease control Recruiting nowThis study aims to evaluate the efficacy and safety of RC148 combined with platinum-based chemotherapy versus Tislelizumab combined with platinum-based chemotherapy in participants with locally advanced or metastatic Squamous NSCLC who have not received first-line treatment. Part…
Phase: PHASE3 • Sponsor: RemeGen Co., Ltd. • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
Gut bacteria therapy shows promise for ulcerative colitis in new trial
Disease control Recruiting nowThe main goal of the study is to check if MH002 works and is safe to use. In a previous study in 45 patients with Ulcerative Colitis, MH002 was found to have favorable effects. In this study, 2 different doses will be tested, and long-term treatment effects will be investigated. …
Phase: PHASE2 • Sponsor: MRM Health NV • Aim: Disease control
Last updated May 16, 2026 05:34 UTC
-
New drug targets tough lung cancer in 60-Patient trial
Disease control Recruiting nowThe aim of the study to evaluate the safety and efficacy of SKB571 for injection as monotherapy in patients with locally advanced or metastatic Non-Small Cell Lung Cancer with MET abnormalities. Eligible subjects will receive SKB571 monotherapy, until radiographic disease progres…
Phase: PHASE2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 16, 2026 05:35 UTC
-
New hope for SMA: yearly injection aims to boost motor function
Disease control Recruiting nowIn this study, researchers will learn more about the effects and safety of BIIB115, also known as salanersen. Specifically, researchers will learn more about how salanersen works in individuals with SMA who are between the ages of 15 and 60 years old. In most people living with …
Phase: PHASE3 • Sponsor: Biogen • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New hope for ovarian cancer: Rina-S combo trial launches
Disease control Recruiting nowThis Phase 3 study will be conducted in different countries around the world with up to about 528 participants. The purpose of this study is to evaluate how well Rina-S works against ovarian cancer in combination with available standard of care therapy that is already approved a…
Phase: PHASE3 • Sponsor: Genmab • Aim: Disease control
Last updated May 07, 2026 18:42 UTC
-
New hope for stomach cancer: combo therapy enters final testing phase
Disease control Not yet recruitingThis is a phase III, Multicenter, Randomized study, evaluating the efficacy and Safety of LM-108(an Anti-CCR8 mAb) in combination With Toripalimab Versus Paclitaxel Injection in subjects with CCR8-Positive locally advanced or metastatic Gastric Cancer and Gastroesophageal Junctio…
Phase: PHASE3 • Sponsor: LaNova Medicines Limited • Aim: Disease control
Last updated May 11, 2026 20:49 UTC
-
New hope for HAE patients: extension study tests long-term attack prevention
Disease control Recruiting nowStudy ADX-324-302 is an extension study for participants who complete the Phase 3 ADX-324-301 trial. The extension study will provide information about the safety and efficacy of additional dosing of ADX-324 in participants with Type I and Type II hereditary angioedema (HAE). The…
Phase: PHASE3 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
Double-barreled cell therapy takes aim at hard-to-treat blood cancers
Disease control Not yet recruitingThis is a single arm study to evaluate the safety and efficacy of CAR19BCMA CAR-T cells in the treatment of relapsed/refractory CD19/BCMA positive plasma cell neoplasms and lymphomas/leukemias with plasmacytic differentiation.
Phase: EARLY_PHASE1 • Sponsor: Affiliated Hospital to Academy of Military Medical Sciences • Aim: Disease control
Last updated May 16, 2026 05:36 UTC
-
Common antibiotic could boost brain bleed recovery
Disease control Recruiting nowThis is a prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial. It aims to evaluate the efficacy and safety of oral minocycline in patients with acute spontaneous intracerebral hemorrhage within 48 hours of onset.
Phase: PHASE3 • Sponsor: Beijing Tiantan Hospital • Aim: Disease control
Last updated May 16, 2026 05:33 UTC
-
New hope for pancreatic cancer? trial tests two drug combos Head-to-Head
Disease control Recruiting nowThis is a single-center, open-label, randomized Phase 2 trial to evaluate the efficacy of NALIRIFOX (Arm 1) vs mGAP (Arm 2) in previously untreated patients with locally advanced (unresectable) and metastatic pancreatic ductal adenocarcinoma (PDAC).
Phase: PHASE2 • Sponsor: Medical University of South Carolina • Aim: Disease control
Last updated May 12, 2026 13:44 UTC
-
New PTSD drug shows promise in large trial
Symptom relief Recruiting nowThis study is evaluating the safety and efficacy of TSND-201 in adults with PTSD. Eligible participants will enter a 4-week Treatment Period where they will be randomized 1:1:1 to receive one of two doses of TSND-201 or placebo, once per week. Following the Treatment Period, par…
Phase: PHASE3 • Sponsor: Transcend Therapeutics • Aim: Symptom relief
Last updated May 13, 2026 15:58 UTC
-
Poop pills may stop deadly infections in pancreatitis patients
Prevention Recruiting nowThe goal of this clinical trial is to learn whether fecal microbiota transplantation (FMT) works to prevent infections complications in patients in the late phase of moderately severe or severe acute pancreatitis.
Phase: NA • Sponsor: Changhai Hospital • Aim: Prevention
Last updated May 01, 2026 16:00 UTC
-
New light gel could save diabetic feet from amputation
Disease control Recruiting nowProtocol No. CHLORIN E6-IIB/III-01/Protocol/1.1 Title:Single-Centre, open-labeled, randomized, Phase IIb and Phase III clinical studies to evaluate the safety, tolerability, and efficacy of Chlorin E6 (Gel Formation) as a photosensitizing agent for the management of Diabetic Foot…
Phase: PHASE3 • Sponsor: United Medical and Dental College • Aim: Disease control
Last updated May 04, 2026 16:20 UTC
-
New blood test could slash unnecessary colonoscopies for colorectal cancer screening
Diagnosis Recruiting nowColorectal cancer is the third most common cancer in men, and the second most common in women. Screening for colorectal cancer is based on the search for blood in the stool using fecal immunochemical test (FIT). Occult bleeding is an indication for colonoscopy. In a FIT positive …
Phase: NA • Sponsor: CHU de Reims • Aim: Diagnosis
Last updated May 15, 2026 11:57 UTC
-
New drug combo shows promise for rare sarcoma in early trial
Disease control Recruiting nowThis is a Phase II, single-arm, multicenter clinical study aimed at demonstrating the effectiveness of benmelstobart injection combined with anlotinib hydrochloride capsules in patients aged 14 years or older with advanced or unresectable alveolar soft part sarcoma by evaluating …
Phase: PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated May 16, 2026 05:34 UTC